Bromodomains (BRDs) are evolutionary conserved epigenetic protein interaction modules which recognize ("read") acetyl-lysine, however their role(s) in regulating cellular states and their potential as targets for the development of targeted treatment strategies is poorly understood. Here we present a set of 25 chemical probes, selective tool small molecule inhibitors, covering 29 human bromodomain targets. We comprehensively evaluate the selectivity of this probe-set using
Introduction
Genetic and epigenetic variation, as well as environmental and lifestyle factors, work in concert to influence human health and disease. In recent years the essential role of epigenetic modifications in regulating gene expression and cellular differentiation has emerged 1,2 . Apart from changes in DNA methylation, covalent post translational modifications (PTMs) of histones and other nuclear proteins define a complex language, the epigenetic code, which regulates chromatin structure and dynamics.
Lysine acetylation (Kac) is a major epigenetic PTM occurring on histone proteins, which has been studied broadly. Kac has generally been associated with activation of transcription through opening of chromatin structure, although some recent studies have found some Kac marks to be responsible for the compaction of chromatin, protein stability, and the regulation of protein-protein interactions 3 .
3 Disruption of histone acetylation patterns has been linked to the development of disease, which may occur through mutations that deregulate enzymes responsible for adding or removing these histone acetyl marks, as well as the protein interaction modules that recognize and interpret this important PTM 4,5 .
Histone acetylation is a highly dynamic process that is regulated by histone acetyltransferase (HAT) and histone deacetylases (HDACs) that respectively "write" and "erase" acetylation marks. The complex pattern of acetylation marks is interpreted ("read") by reader domains of the bromodomain (BRD) family of proteins. BRD-containing proteins are evolutionary conserved and of substantial biological interest, as components of transcription factor and chromatin modifying complexes and determinants of epigenetic memory. There are 61 BRDs expressed in the human proteome, present in 46 diverse proteins. However, some atypical bromodomains, which lack essential residues have little or no-activity towards Kac-containing histone sequences and may recognize other epigenetic marks or unmodified peptide sequences, while canonical BRDs may also bind to complex patterns of modification around a central Kac site that often contain other post translational modifications 6, 7 .
The modular nature of many BRD-containing proteins, which typically harbour a number of diverse reader domains in addition to enzymatic functionalities and role(s) as scaffolds in large chromatin modifying complexes, makes their functional study a challenging task. However, the development of highly selective inhibitors has provided versatile tools for functional studies on endogenous BRD-containing proteins which can now be used to unravel the role of the epigenetic Kac-dependent reading process in chromatin biology as well as in the development of disease. This is exemplified by the development of highly potent inhibitors for BET (Bromo and extra-terminal; BRD2, BRD3, BRD4, BRDT) BRDs 8, 9 , which has led to numerous translational and functional 4 studies on this subfamily of bromodomain proteins [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Chemical probes, small molecule tool inhibitors with selectivity against similar proteins, have led to the validation of many disease targets, making seminal contributions to our understanding of complex cellular processes. However, chemical probes need to be highly selective, cell active and therefore need to be comprehensively characterized in order to link observed phenotypic responses to targeted proteins. Unfortunately, selectivity and potency of tool compounds are often insufficient resulting in contradictory and erroneous results [19] [20] [21] [22] . Following the disclosure of potent BET BRD inhibitors, other members of the BRD-family of interaction modules have been found to be highly druggable 23 , resulting in the identification of chemical fragments that were subsequently developed into potent and selective chemical probes [24] [25] [26] [27] [28] [29] [30] [31] . However, BRDs outside the BET family have not been found to be major regulators of primary transcription control, posing challenges for the discovery of functional roles of these conserved domains 32 . As a result, only a few studies have reported phenotypic consequences inhibiting non-BET BRDs pointing to important roles in cellular differentiation 33, 34 .
Here, we characterized a comprehensive set of BRD chemical probes covering all subfamilies previously identified with good druggability scores 23 . Using a standardized commercial assay format (BROMOscan ® ), based on a high throughput binding assay originally developed to assess the selectivity of kinase inhibitors 35 , we evaluated the selectivity of this BRD chemical probe-set and determined a total of 626 K D values on all detected interactions. We present here an overview of the binding modes of these inhibitors resulting in the excellent selectivity of these chemical probes. To exemplify the use of this probe-set in biological systems, we further screened this probe collection on a cellular model of muscle differentiation identifying BET BRDs as major regulators in this context.
Furthermore, systematic investigations of all existing BRD inhibitors in triple negative breast cancer (TNBC) cell lines have revealed an essential role of BRD inhibitors to target the metabolic vulnerability of TNBC, demonstrating their utility as a collection to uncover previously unknown crosstalk between epigenetic regulators and cell metabolism. Together, our study provides a comprehensive structural and functional insight on BRD inhibitors, establishing a powerful resource for future mechanistic studies of this family of epigenetic reader domains, and underscoring the broad utility and immediate therapeutic potential of direct-acting inhibitors of human bromodomain proteins.
Results

A set of highly selective bromodomain probes
BRDs have been grouped into eight major families based on sequence and structural homology 6 (Figure 1 ). Potent chemical probes have now been developed for most of these families with the notable exception for BRDs of the PML (promyelocytic leukemia)-SP100 nuclear bodies (family V), which harbor a PHD-BRD tandem reader cassette. However, some families are still insufficiently covered, including members of families VI and VII which also have atypical and shallow Kac-binding pockets. In contrast, family I which contains the histone acetyltransferases PCAF and GCN5 as well as CECR2 and FALZ is well covered by chemical probes. To date, the BET BRDs (Family II) have had the greatest activity in inhibitor development, undoubtedly due to the strong and clinically relevant phenotypes observed for these compounds.
This is an area that has rapidly evolved and has been previously reviewed in detail 10, 40 45 . Here we included in our probe set JQ1, I-BET151 and PFI-1 as three structurally diverse and unencumbered chemical probes for BET proteins.
Family III contains BRDs present in the histone acetyl-transferases (HATs) p300 and CBP, as well as a number of diverse BRDs for which no potent inhibitors have been identified so far. The first inhibitor developed for CBP/p300, SGC-CBP30, exhibited potent activity for BRDs in these two HATs (K D : 21 and 38 nM, respectively), retaining however significant BET activity, which needs to be taken into account in cellular assays by using appropriate concentrations 29, 46 . The chemical probe set presented here comprises 25 tool compounds covering 29 (50%) of all human BRD proteins (Supplemental Table S1 ). Each chemical probe interferes with the binding of 8 its respective BRD(s) acetyl-lysine target sequences including the major acetylation sites described as BRD binding sites on histone proteins (Figure 2 ) 6 . (Figure 3) . We used ITC as a standard for the accurate determination of binding constants, given its capacity to directly measure ligand binding in solution. All three assays resulted in comparable data ( Figure 3B ). However, while correlation between ITC and BROMOscan ® data was excellent ( Figure 3D ), some BRDs exhibited smaller than expected T m shifts based on their binding constants determined by ITC ( Figure 3E ). In particular, BSP showed only modest T m shifts against TAF1L(2) and BRD9 and a relatively large shift against CBP, compared to the directly determined ITC dissociating constants (K D s). Encouraged by the accuracy of the BROMOscan ® assay, we screened 15 chemical BRD probes against all 42 BRD-containing proteins and determined a total of 626 dose response curves (Supplemental Table S2 ). In addition to the BRD-probe set, we included three closely related variants of chemical probes within our set, CBP30-298 and CBP30-383 which are closely related to SGC-CBP30, as well as PFI-3 D1, a close derivative of PFI-3 (Supplemental Figure S1 ) 29, 33, 57 . However, while CBP30-related BET off-target effects were also apparent in the two additional CBP30 derivatives, the exclusive selectivity of PFI-3 towards SMARCA2/4 and PB1 was maintained in the derivative PFI-3 D1. Interestingly, the Kac mimetic salicylic acid head group of PFI-3 and its derivatives showed selectivity for this bromodomain subfamily. This striking observation has been rationalized by the unique binding mode of family VIII inhibitors that penetrated deeper into the Kac binding site leading to displacement of water molecules that are maintained in other BRD-inhibitor complexes 58, 59 . In summary, BROMOscan ® offers a robust platform for accurate K D determination of BRD inhibitors, and chemical probes screened here maintained at least a 30-fold selectivity window against BRD in other families.
Selectivity of bromodomain chemical probes
BET chemical probes block muscle cell differentiation by down-regulation of myogenin
Several BRD-containing proteins are known to be essential for different types of cellular differentiation, including myogenesis 33, 34, 57, 60 . During myogenesis, differentiating myoblasts fuse to form multinucleated myotubes/myofibers, a process that plays an important role in development and regeneration, and BET proteins have recently been implicated in this process 61 . Given the importance of muscle regeneration in human health, we were interested in determining whether BRD inhibition would modulate the ability of muscle progenitor cells to undergo terminal differentiation. To explore this, the muscle progenitor C2C12 cell line was cultured in conditions of low serum to initiate differentiation in the presence of diverse BRD inhibitors from the chemical probe-set described here. Strong inhibitory effects of myoblast differentiation were seen for the BET inhibitor JQ1 as well as the pan-BRD inhibitor BSP, but not for other BRD inhibitors ( Figure 4A and B). To gain insight into the transcriptional effects resulting from BRD inhibition, we performed gene expression analysis ( Figure 4C ). In agreement with our observations on myoblast differentiation, treatment with JQ1 and BSP resulted in significant changes in gene expression levels. Importantly, promiscuous targeting of BRD-proteins using BSP resulted in almost identical changes in gene expression compared to JQ1, strongly suggesting that the inhibition of differentiation is due to BET BRDs and not due to inhibition of other BRD-containing proteins. In agreement with this observation, expression changes resulting from targeting of other specific BRD-inhibitors outside the BET family were negligible ( Figure 4C ). Most significantly, differential expression analysis identified several anti-proliferative and anti-inflammatory genes downregulated including proteins modulating interferon response such as IFIT3 (interferon induced protein with tetratricopeptide repeats 3), interferon induced GTP hydrolases (GBPs) and USP18 (Ubiquitin Specific Peptidase 18) ( Figure   5A and B). Gene-set enrichment analysis (GSEA) resulted in strong signatures for anti-inflammatory pathways and cell cycle regulators as well as myogenesis ( Figure 5C ; Supplemental Figure S2 ). Gene Ontology (GO) analysis corroborated these observations identifying enriched biological processes relating to cell cycle and mitosis as well as immune system processing and innate immune response ( Figure 5D , Supplemental Figure S2 ). In particular, transcription of genes regulating expression of myosin light-and heavy-chains as well as regulators of myosin, such as myosin light chain kinase (MLCK) and myotonic dystrophy associated protein kinase (DMPK) and the tintin-associates proteins myomesin 1 and 2, was strongly suppressed. Key regulators of cellular fusion, important for the late stages of myogenesis, such as the protease ADAM12 were also affected. Importantly, we observed strong down-regulation of the muscle-specific basic-helix-loop-helix transcription factor myogenin (myogenic factor 4), a protein whose induction acts as a "point-of-no-return" in myogenesis by inducing cell cycle exit and activation of muscle-specific genes [62] [63] [64] [65] . These observations suggest therefore that transient inhibition of BET bromodomain-containing proteins may be a means to delaying myoblasts from 11 undergoing terminal differentiation. Interestingly, we did not observe transcriptional regulation of MYC and its target genes (Supplemental Figure S2) However, no significant growth inhibitory effects were observed for the remaining BRDis.
Metabolism can directly impact cellular epigenetic landscapes and alter responses to chemo-therapeutics
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. In particular, acetylation of histones relies on the availability of the universal acetyl donor metabolite acetyl-CoA, which is biosynthesized by breakdown of carbohydrates through the glycolytic pathway. Many TNBC cell lines display a classical Warburg metabolism with up-regulated glucose uptake to fuel their bioenergetics and biosynthetic demands 73, 74 . We confirmed that the set of 10 TNBC cell lines investigated in this study had a range of metabolically distinct states and variable global levels of histone acetylation (Supplemental Figure S3A- 
C).
Furthermore, compared to other breast cancer subtypes, TNBC cell lines have a higher glycolytic gene-expression signature, especially for glucose transporter I (GLUT1) expression ( Figure 6B ), and thus tend to be more sensitive to glucose depletion
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. Accordingly, this led us to investigate whether disruption of glycolysis in TNBC lines can give rise to epigenetic vulnerabilities to BRDis.
Using the selective GLUT1 inhibitor, BAY-876 76 , we first confirmed that exposure to BAY-876 inhibits glucose uptake in TNBC lines ( Figure 6C, S3D ). We then assessed the impact of BAY-876 treatment on levels of metabolites related to glycolysis and relevant to histone acetylation level.
Acetyl-CoA is at the crossroads of glycolysis and TCA cycles and is the cofactor for histone acetyltransferases (HATs) 77, 78 . Upon treatment with BAY-876, a decrease in absolute acetyl-CoA level was observed, suggesting that HAT activity might be perturbed by BAY-876 treatment ( Figure   6D ). Another essential player involved in metabolism and acetylation is the NAD + /NADH ratio, which is closely associated with energy status in cell and is thought to positively regulate the activity of sirtuins 79 . We observed an increase in the NAD + /NADH ratio which may lead to increased sirtuin activity, possibly also contributing to histone hypo-acetylation ( Figure 6E ). Having observed a change in metabolites known to be involved in protein acetylation in response to BAY-876, we next investigated whether there are corresponding changes in histone acetylation levels. Interestingly, we detected a reduction in the global levels of acetylated histone H3 (ac-H3), but not in the global levels of acetylated histone H4 (ac-H4), in response to BAY-876 treatment ( Figure 6F ). These results demonstrate that manipulating metabolic flux by inhibiting glucose uptake can specifically impact the acetylation on individual histones.
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We next assessed whether altered histone acetylation induced by BAY-876 treatment could induce sensitivity to BRDi in TNBC cell lines. We performed a combinatorial screen on three TNBC lines with distinct glycolytic rates (Supplemental figure S3 C). BAY-876 treatment alone had no effect on these three TNBC lines ( Figure 6G ), but in combination with the chemical probes PFI-1, OF-1 and I-BRD9 we observed a significant decrease in viability ( Figure 6H ). The activity of OF-1 was of particular interest due to the strong synergistic effect across all three cell lines, whereas JQ1 and I-BRD9 combinations with BAY-876 showed efficacy in only one of the three tested TNBC lines ( Figure 6H ).
To better understand the mechanism of the BAY-876/OF-1 combination, we determined the IC 50
values for OF-1 treatment in all three cell lines. In the presence of 3 μM BAY-876, we observed IC 50
values for OF-1 in the range of 0.3-2 μM ( Figure 7A ). An increase of OF-1 sensitivity was also observed in response to glucose deprivation mimicking the effect of BAY-876 treatment ( Figure 7B ).
The combinatorial effect of BAY-876 and OF-1 was more than additive because the BAY-876 concentration we used in this assay has no overt effect on cell growth based on colony formation assay (Supplemental figure S3E). We next examined whether the observed synergy is due to the induction of apoptosis by the combination. Indeed, apoptosis markers such as caspase 3/7 were induced at a significantly higher level in combination-treated cells compared with cells treated with either OF-1 or BAY-876 alone (Supplemental figure S3F) . Thus, we conclude that OF-1 and BAY-876 are synergistic in suppressing the growth of TNBCs by inducing apoptotic cell death.
OF-1 inhibits Kac binding of the BRDs of BRPF1, BRPF2 and BRPF3. In order to deconvolute which BRD proteins are responsible for the observed phenotype with BAY-876, we compared the combinational effect on TNBC cell viability with another potent pan BRPF inhibitor NI-57, and the 14 selective BRPF1 inhibitor PFI-4. Co-treatment with BAY-876 and OF-1 led to the strongest reduction on the cell viability, whereas other combinations were less effective ( Figure 7C ). Moreover, no significant effect was observed in the PFI-4 combination, which excludes the role of BRPF1 in the synergy effect. In agreement with these results, siRNA knockdown of BRPF1 did not change the cell sensitivity to BAY-876 treatment ( Figure 7D-F) . Notably, compared to the single BRPF2 or BRPF3
knockdown, the cells with dual BRPF2/3 knockdown are more sensitive to BAY-876 treatment ( Figure 7F ). Together, these results demonstrate that the observed synergy effects are due to the inhibition of BRPF2 or/and BRFP3 by OF-1.
BRPF2 and BRPF3 are components of the HBO1 (KAT7) acetyltransferase complex, while BRPF1
preferentially participates in the MOZ/MOF complex 80, 81 . Furthermore, BRPF2/3/HBO1 complexes were also shown to be important and specific for the HAT activity toward H3K14, whereas the BRPF1 complexes have high specificity on H4 acetylation marks 81 . To explore whether the inhibition of BRPF2 or/and BRPF3 has any effect on histone acetylation, we measured the H3K14ac level upon treatment with BRPF BRD chemical probes, or in BRPF knockdown cell lines. Compared to NI-57 and PFI-4, the acetylation of H3K14 was significantly decreased in the presence of OF-1 (Figure 7G, S2G) . Likewise, dual BRPF2/3 knockdown displayed the strongest reduction of H3K14ac compared to BRPF2 or BRPF3 knockdown alone ( Figure 7H, S2H) . Taken together, these data are consistent with a model in which inhibition of glucose up-take by BAY-876 and antagonism of HBO1 subunits BRPF2/3 by OF-1, both converge on the same histone marks, leading to synergistic cross talk between metabolic and epigenetic pathways ( Figure 7I ).
Discussion
Recent effort by our laboratories and others established a comprehensive set of epigenetic probe molecules for selective targeting of acetyl-lysine dependent reader domains. We believe that this is significant achievement considering that apart from a number of fragment-like small molecules, no BRD had been targeted before the first potent BET inhibitors were disclosed in 2010 8, 9 . [85] [86] [87] . The combination of different inhibitors might also be important in overcoming drug resistance which has been observed in cells treated with BET inhibitors
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. The reported surprising dual activity of kinase and BET inhibitors suggests that potent activity for both bromodomain and kinases could be designed into a single inhibitor [88] [89] [90] [91] .
The profiling data provided here offers a comparison of inhibitor potency and selectivity across the BRD family. We found good correlation of BROMOscan ® assay data with K D s determined in solution by ITC, whereas the magnitude of T m shits across the BRD family may vary depending on the intrinsic stability of each BRD. However, as an analytical tool the T m shift assay provides a good platform for assessment of selectivity when hits are carefully followed up using orthogonal binding assays. Some probe compounds were exclusively selective while others, such as the CBP/p300 probes I-CBP112 and CBP30, showed significant BET activity (Supplemental Table S2 ). Thus, care should be taken when these probes are used in cellular assays. We recommend that probe concentration not higher than 3 μM for I-CBP112 and 2.5 μM for CBP30 are used in cell-based assays and that BET inhibitors are included as controls. Post-immunofluorescence, differentiation index was calculated by counting the number of nuclei in myosin heavy chain expressing myotubes divided by the total number of nuclei per field. C)
Heatmap of the top 50 statistically significant genes that were differentially expressed (using Benjamini-Hochberg adjusted P-value < 0.001) following 12 h treatment with specific BRD inhibitors. Graph indicate mean and error bars denote standard deviation from three independent assays and p value computed using Benjamini-Hochberg t test; ** p<0.01; *** p<0.001. 
